再鼎医药（上海）有限公司 ZAI LABORATORY
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates 2022-05-11 15:13
Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates 2020-08-13 22:38
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor 2020-07-20 22:39
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China 2020-07-08 11:37
Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer 2020-05-29 07:05
Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam- Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections 2020-05-19 09:45
Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates 2020-03-20 00:21
1